New drug combo aims to slow advanced lung cancer

NCT ID NCT04699838

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times

Summary

This study tests a new treatment plan for people with extensive stage small cell lung cancer who have not had treatment before. Participants first get standard chemo-immunotherapy, then a maintenance therapy with two drugs: durvalumab and ceralasertib. The goal is to see if this combination can delay cancer growth. About 30 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Illinois Medical Center

    RECRUITING

    Chicago, Illinois, 60612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Iowa Hospitals and Clinics

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact Email: •••••@•••••

    Contact

  • University of Maryland

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.